
Hologic Joins NEST Governance Committee to Advance the Use of Real-World Data in Medical Device Evaluation
The National Evaluation System for health Technology (NEST), an initiative of the Medical Device Innovation Consortium (MDIC), is pleased to welcome Hologic, a leading global medical device and diagnostic company, to its Governance Committee. This appointment reflects Hologic's commitment to advancing the use of real-world data (RWD) to support medical device evaluation and drive innovation in women's health.
Hologic is the latest partner to join the NEST Governance Committee which convenes a diverse group of leaders from across the medical device ecosystem—including regulatory agencies, industry, academia, patient organizations, and health systems.
NEST's mission aims to accelerate patient access to life-changing innovation by supporting the sustainable generation and use of timely, reliable and cost-effective real-world evidence (RWE) solutions throughout the medical device total product lifecycle. To advance this mission, NEST's Governance Committee plays a pivotal role by jointly identifying and prioritizing key initiatives that drive RWE generation for medical devices in support of regulatory submission packages, all while ensuring a patient-centered, inclusive, accountable, and transparent approach.
'Hologic is honored to join the NEST Governance Committee and contribute to advancing the use of real-world evidence in diagnostic and medical device evaluation,' said Jeff Hergesheimer, Senior Director, Regulatory Affairs at Hologic and newly appointed NEST Governance Committee member. 'Real-world data plays a critical role in accelerating innovation and improving patient outcomes. Through collaboration with NEST and other stakeholders, we look forward to driving solutions that enhance regulatory decisionmaking and deliver impactful healthcare advancements.'
Through NEST Governance Committee involvement, Hologic will help accelerate patient access to cutting-edge technologies, bring a unique perspective as an industry leader in women's health, and contribute to the evolution of RWE approaches in regulatory decision making. Through its contributions, Hologic brings a valuable perspective grounded in both technical expertise and an enduring commitment to innovation in women's health.
'We are thrilled to welcome Hologic and Jeff to the NEST Governance Committee,' said Simon Mason, president at NEST. 'Their pioneering leadership in women's health meets an untapped need on our committee coupled with their commitment to employing RWE in regulatory submissions will bring invaluable insights and experience and most importantly, improve patient care and quality of life.'
For more information about Hologic, visit https://www.hologic.com.
About Hologic, Inc.
Hologic, Inc. is a global leader in women's health dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. To learn more, visit www.hologic.com and connect with us on LinkedIn,Facebook,X,Instagram and YouTube.
About NEST (National Evaluation System for health Technology)
In 2016, the U.S. Food and Drug Administration (FDA) awarded the Medical Device Innovation Consortium (MDIC) funding to establish the National Evaluation System for health Technology Coordinating Center (NEST). NEST is advancing the use of real-world evidence (RWE) in medical devices for regulatory decision-making and committed to transforming the way medical device technologies are tested, approved, and monitored. The Coordinating Center combines RWE system infrastructure with the unparalleled expertise of its network collaborators to accelerate patients' access to safe and effective medical technology and provide Quality Evidence by Design™. For more information on NEST, please visit nestcc.org or connect with us on LinkedIn.
About MDIC (Medical Device Innovation Consortium)
At MDIC, we unite in a shared mission to improve health and save lives by accelerating access to medical technologies. Through stakeholder collaboration, MDIC leads the way in advancing the scientific and technical foundations of medical device design, manufacturing, regulation, reimbursement and clinical integration. Founded in 2012 as a nonprofit, public-private partnership to elevate regulatory science, MDIC develops new approaches and tools for addressing shared challenges among medical device manufacturers, researchers, regulators, payers, patients, and health care providers. We deliver high impact work in the core areas of quality design and manufacturing, evidence generation, digital technology and transformation, and patient engagement. To learn more and join us in our mission, visit MDIC.org.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250602971620/en/
CONTACT: Media Contacts:
Bridget Perry
Sr. Director of Communications
[email protected] Victoria
Vice President, Brand and Experience
MDIC
[email protected] Investor Contact:
Michael Watts
Corporate Vice President, Investor Relations
[email protected]
KEYWORD: VIRGINIA UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: OTHER HEALTH PROFESSIONAL SERVICES DATA MANAGEMENT TECHNOLOGY MEDICAL DEVICES HEALTH TECHNOLOGY DATA ANALYTICS SCIENCE MEDICAL SUPPLIES FDA OTHER TECHNOLOGY HEALTH OTHER SCIENCE
SOURCE: Medical Device Innovation Consortium
Copyright Business Wire 2025.
PUB: 06/02/2025 11:03 AM/DISC: 06/02/2025 11:02 AM
http://www.businesswire.com/news/home/20250602971620/en
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Green Hydrogen Production Group Closes on Major Investment
A California-based hydrogen production group said it has completed a funding round in support of the company's first 100-kilotonne carbon dioxide removal (CDR) commercial facility. Equatic, which is considered a pioneering company in combined carbon dioxide removal and green hydrogen production, on August 11 announced the successful closure of its Series A round, with Catalytic Capital for Climate and Health (C3H) leading an $11.6-million investment. C3H is a catalytic vehicle by Temasek Trust, along with Kibo Invest, a Singapore-based private investment office with a focus on climate technology. The funding round, with participation from a consortium of global investors, will accelerate the engineering scale-up and commercialization of Equatic's patented seawater electrolysis technology. This substantial capital infusion will support the ongoing engineering of Equatic's CDR commercial facility, alongside further commercialization, manufacturing, and technological development. Equatic's proprietary technology is designed to capture atmospheric carbon dioxide and produce green hydrogen in a single, scalable process, advancing two critical net-zero pathways. 'This investment marks a pivotal moment for Equatic, enabling us to significantly scale our production capabilities and accelerate our mission to deliver durable carbon removal at scale,' said Gaurav N. Sant, founder and chief technology officer for Equatic. 'The Temasek Trust ecosystem has been a foundational partner to Equatic, from early-stage philanthropic backing from Temasek Foundation to catalytic investment through C3H. We welcome Kibo Invest as co-lead and recognize their commitment to invest in companies that are revolutionizing industries and addressing urgent climate challenges.' 'Truly innovative carbon management technologies are needed to mitigate climate change before the consequences become irreversible,' said Lord John Browne, chairman of Equatic's advisory board. Browne also is founder and chairman at BeyondNetZero, and the former CEO of British Petroleum. 'By removing carbon dioxide and simultaneously generating green hydrogen, Equatic's solution provides unique advantages in terms of cost and scalability.' Ryan Tan, head of C3H, said, 'Equatic's technology and approach exemplify the type of bold and scalable innovation that aligns with C3H's mandate. We are delighted to support Equatic's goal in advancing promising climate mitigation solutions that offer permanent, durable carbon removal with green hydrogen production for scalable, tangible impact and commercial benefit.' 'Equatic represents an exciting opportunity to scale deep-tech innovation that addresses two critical needs: decarbonisation and clean energy. As an investor focused on climate solutions, we are proud to partner with C3H and Equatic to help bring this breakthrough technology to commercial scale,' said James Marshall, CEO of Kibo Invest. Equatic's Technology Since commencing operations in 2023, the Equatic technology has been successfully deployed at two pilot plants in Los Angeles and Singapore. The company is now expanding its operations with a demonstration plant in Singapore, known as Equatic-1, and a commercial-scale plant in Canada. In May 2024, Equatic was recognized as a CDR Purchase Prize semifinalist by the U.S. Department of Energy, acknowledging its high-quality, permanent carbon credits and rigorous Monitoring, Reporting, and Verification (MRV) practices. In September 2024, Equatic announced a significant climate breakthrough with the U.S. manufacture of oxygen-selective anodes, which unlock scalable hydrogen production through direct seawater electrolysis. That same month, Equatic was named a finalist for The Earthshot Prize, a prestigious international recognition for groundbreaking solutions to repair the planet. Equatic's commitment to high-integrity carbon removal is underscored by its adoption of an ISO-14064 standard for MRV, first published by Equatic in May 2023. Subsequently, this standard was validated by two leading carbon removal registries, Isometric and making Equatic one of the only marine companies capable of issuing high-quality CDR credits under either registry, with full transparency and auditability. Buyers of Equatic's CDR credits include Boeing, a leading global aerospace company and other large industrial companies committed to market-based mechanisms for decarbonization. —POWER edited this content, which was contained in a press release from Equatic.
Yahoo
27 minutes ago
- Yahoo
Mizuho Lowers PT on Acadia Healthcare Company (ACHC) to $22 From $32, Keeps a Neutral Rating
Acadia Healthcare Company, Inc. (NASDAQ:ACHC) is one of the top cheap stocks that will go to the moon according to Reddit. On August 14, Mizuho analyst Ann Hynes lowered the firm's price target on Acadia Healthcare Company, Inc. (NASDAQ:ACHC) to $22 from $32, keeping a Neutral rating on the shares. A healthcare professional discussing a treatment plan with a patient in an outpatient clinic. The rating update came after Acadia Healthcare Company, Inc. (NASDAQ:ACHC) reported fiscal Q2 results that missed consensus estimates when excluding the incremental effect of direct provider payments in the quarter. The firm slashed its 2025-2027 adjusted EBITDA estimates and is staying on the sidelines, attributing the stance to 'execution missteps' and uncertainty regarding the effects of the ongoing Medicaid Redeterminations and the One Big Beautiful Bill Act. Acadia Healthcare Company, Inc. (NASDAQ:ACHC) provides behavioral healthcare services across the US in various settings, including inpatient psychiatric hospitals, residential treatment centers, specialty treatment facilities, and outpatient clinics. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
27 minutes ago
- Yahoo
Bernstein Reiterates a Buy Rating on Charter Communications (CHTR), Sets a $380 PT
Charter Communications, Inc. (NASDAQ:CHTR) is one of the top cheap stocks that will go to the moon according to Reddit. In a report released on August 12, Laurent Yoon from Bernstein reiterated a Buy rating on Charter Communications, Inc. (NASDAQ:CHTR), setting a price target of $380.00. A line of cable boxes and modern televisions, representing the company's video services. Charter Communications, Inc. (NASDAQ:CHTR) reported its fiscal Q2 results on July 25, with total Internet customers decreasing by 117,000. Total mobile lines for the quarter rose by 500,000. As of June 30, Charter Communications, Inc. (NASDAQ:CHTR) serves 29.9 million Internet customers, 10.9 million mobile lines, and 31.2 million customer relationships (excluding mobile-only relationships). Charter Communications, Inc. (NASDAQ:CHTR) also reported that revenue for Q2 rose 0.6% year-over-year to $13.8 billion, supported by residential mobile service revenue growth of 24.9%, residential Internet revenue growth of 2.8%, and other revenue growth of 18.9%. Charter Communications, Inc. (NASDAQ:CHTR) provides broadband communications services. The company's offerings include Spectrum TV, Spectrum Internet, and Spectrum Voice. Charter Communications, Inc. (NASDAQ:CHTR) also offers data networking, business-to-business Internet access, video and music entertainment services, business telephone, and wireless backhaul. While we acknowledge the potential of XXXX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data